Results and Key Takeaways From the TriMM-2 Study in Patients With RRMM

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for isatuximab combination treatment in the first article of a 2-part series.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed how to implement use of bispecific T-cell engagers in patients with relapsed/refractory multiple myeloma in the second article of a 2-part series.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

The ready-to-use formulation of bortezomib is now an FDA-approved option for patients with multiple myeloma and mantle cell lymphoma.

During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed the MonumenTAL-1 trial of talquetamab in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.